Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company - Seite 2

# # #

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz  
Twitter: https://twitter.com/sandoz_global 
Facebook: https://www.facebook.com/sandozglobal/ 
Instagram: https://www.instagram.com/sandoz/global 

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

# # #

Sandoz Global Communications
Central			North America
Chris Lewis		[phone]	Leslie Pott	[phone]
Novartis Media Relations E-mail: [e-mail]
Central			North America
Richard Jarvis	[phone]		Julie Masow	[phone]
Switzerland Satoshi Sugimoto	[phone]
Novartis Investor Relations Central investor relations line: [phone] E-mail: [e-mail]
Central			North America
Samir Shah		[phone]	Sloan Simpson	[phone]
Nicole Zinsli-Somm		[phone]	Parag Mahanti	[phone]
Isabella Zinck		[phone]